Phoenix, AZ , Nov. 20, 2017 -- Uptick Newswire announces interview by host Everett Jolly of returning guest Andy Whelan President of BioElectronics Corp. (OTC: BIEL, the “Company”). Starting off the interview, Mr. Whelan presented an overview of the Company’s pain products, its domestic and international sales, and clinical trials status. The interview may be heard at https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-2
BioElectronics has US FDA market clearance for two wearable OTC neurological medical devices, significant international distributors, and a technology platform for a host of additional products. The current developed product line includes:
- RecoveryRx® for Postoperative and Chronic Wounds,
- Allay® Menstrual Pain Therapy,
- Smart Insole™ for Heel Pain; and,
- ActiPatch® Musculoskeletal Pain Therapy.
Our neurological disorder technology platform will produce without burdensome expense products for fibromyalgia, overactive bladder, diabetic neuropathy, chronic tinnitus,migraine headaches (clinical study currently being finalized) etc.
We are launching US sales through a leading wholesaler that distributes generic, brand, specialty, and over-the-counter pharmaceutical products to over 10,000 retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices. Additionally, we expect to have product in at least one of the major drugstoresand several mini chains in 2018.
We will be promoting a money back guarantee on the 30-Day ActiPatch® Musculoskeletal Pain Therapy device by packaging it with the 7-Day Trial device. Try the 7-Day trial device and if you are not satisfied return the trial unit and get a full refund.
International sales are progressing well with a new distributor for Spain and Portugal, an expansion of PharmEvo,our Vietnam distributor, into Cambodia and Maldives. PharmEvo is also contracting for additional Southeast Asia territories of the Philippines, Pakistan, Indonesia, and Malaysia.
In closing Andy stated, “We have an outstanding product line making BioElectronics a very substantial company without additional expense and debt. We have a pipeline of products that we just pump out and make it a very substantial company without incurring additional expense and debt.”
About BioElectronics Corporation: A leader in noninvasive neuromodulation pain therapy and makes: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; Smart Insole™ for Heel Pain, RecoveryRx® Devices for chronic wounds and post-operative wound care; and Allay® Menstrual Pain Therapy. For clinical and more information, please visit www.bielcorp.com.
Source: Uptick Newswire
Contact: Paul Knopick 940.262.3584 [email protected]


Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



